Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Clean conscious formulation
The only difference is which copper peptide variant is used
That said, the compound has not been through full Phase III trials or FDA drug approval
The primary endpoint was not met
In a 26-week rat oral toxicity study, AOD-9604 produced dose-dependent changes in serum osteocalcin (a bone-turnover marker) at week 13, with the direction reversing by week 26
When adverse effects occurred, they were typically mild and transient, with the most common being mild to moderate headaches (similar frequency to placebo groups), minor injection site reactions (redness, slight swelling), and gastrointestinal effects at higher oral doses (nausea, diarrhea)
US$ 26.54
US$ 26.98
US$ 23.10
US$ 23.90
